Emergency Contraceptive's Length Of Efficacy Likely Focus Of FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The Reproductive Health Drugs Advisory Committee will consider the the five-day claim sought by HRA Pharma's Ella (ulipristal acetate) which would give it a two-day advantage over Teva's Plan B (levonorgestrel) in preventing pregnancy after unprotected intercourse.
You may also be interested in...
Ella And Plan B: Complementary, Competitive Or Confusion?
HRA Pharma's emergency contraceptive Ella (ulipristal acetate) is effective up to five days after unprotected intercourse or contraceptive failure, overlapping with the three-day efficacy period of Teva's Plan B (levonorgestrel). But whether the result will be harmonious market niche carving or confusion remains to be seen
Ella And Plan B: Complementary, Competitive Or Confusion?
HRA Pharma's emergency contraceptive Ella (ulipristal acetate) is effective up to five days after unprotected intercourse or contraceptive failure, overlapping with the three-day efficacy period of Teva's Plan B (levonorgestrel). But whether the result will be harmonious market niche carving or confusion remains to be seen
PregLem Weighs Financing Options Well Ahead Of Uterine Fibroid Drug Launch
Esmya, an oral therapy being developed for symptomatic uterine fibroids, showed non-inferiority to GnRH agonists in a Phase III study.